Management of toxicities associated with high-dose interleukin-2 and biochemotherapy

Anti-Cancer Drugs

Volumn 24, Issue 1, 2013, Pages 1-13

  Poust, Jamie C ^a   Woolery, Joseph E ^b   Green, Myke R ^c,d,e  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b Banner MD Anderson Cancer Center   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Aldesleukin; Biochemotherapy; Immunotherapy; Interleukin 2; Melanoma; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ATROPINE PLUS DIPHENOXYLATE; BICARBONATE; CALCIUM CARBONATE; CISPLATIN; CREATINE KINASE; CREATININE; DACARBAZINE; DOPAMINE; FUROSEMIDE; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 2; LOPERAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OPIATE; PHENYLEPHRINE; PHYTOMENADIONE; PLATINUM DERIVATIVE; POTASSIUM; PROTON PUMP INHIBITOR; PSEUDOEPHEDRINE; TROPONIN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

ACIDOSIS; ANEMIA; ANOREXIA; ANURIA; ANXIETY; ARTHRALGIA; AUDITORY HALLUCINATION; AUTOIMMUNE THYROIDITIS; BACTEREMIA; BACTERIAL INFECTION; BACTERIURIA; BILIRUBIN BLOOD LEVEL; BIOLOGICAL THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; BULLOUS DERMATITIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CATHETER INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DELIRIUM; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; EPIGASTRIC PAIN; ERYTHROCYTE TRANSFUSION; ERYTHRODERMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTRITIS; HAIR DISCOLORATION; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER FUNCTION TEST; LUNG CONGESTION; LYMPHOCYTOPENIA; MALAISE; MENTAL INSTABILITY; METASTASIS; METASTATIC MELANOMA; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS; MYOCARDITIS; MYOSITIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NOSE OBSTRUCTION; OLIGURIA; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PIGMENT DISORDER; PLEURA EFFUSION; PRACTICE GUIDELINE; PREMEDICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; PSORIASIS; RASH; RECURRENCE FREE SURVIVAL; RESPIRATORY DISTRESS; REVIEW; RHABDOMYOLYSIS; RIGOR; SEPSIS; SIDE EFFECT; SINUS TACHYCARDIA; SKIN DISEASE; SKIN EXFOLIATION; SOMNOLENCE; STAPHYLOCOCCUS INFECTION; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TH1 CELL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROTOXICOSIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA; URINARY TRACT INFECTION; VIRUS INFECTION; VISUAL HALLUCINATION; VITILIGO; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MELANOMA; NEOPLASM METASTASIS; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TIME FACTORS;

EID: 84870932911     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835a5ca3     Document Type: Review

References (86)

1. Weber J. Immunotherapy for melanoma. Curr Opin Oncol 2011; 23: 163-169.
2. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer - when TKIs are not enough. Nat Rev Clin Oncol 2009; 6:478-487.
3. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981; 291:335-338.
4. Loose D, Van de Wiele C. The immune system and cancer. Cancer Biother Radiopharm 2009; 24:369-376.
5. Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the 'self' to destroy the 'other'. Crit Rev Immunol 2000; 20:433-450.
6. Hamm C, Verma S, Petrella T, Bak K, Charette M. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008; 34:145-156.
7. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-485.
8. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696.
9. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141.
10. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11:661-670.
11. Negrier S, Escudier B, Lasset C, Douillard J-Y, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272-1278.
12. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132.
13. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21:3133-3140.
14. Rosenberg SA, Yang YC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J Am Med Assoc 1994; 271:907-913.
15. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
16. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748-5754.
17. McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000; 6: 2201-2208.
18. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-2052.
19. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa- 2b. J Clin Oncol 1999; 17:968-975.
20. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25:5426-5434.
21. O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HS, Martin M. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002; 8:2775-2781.
22. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007; 25:3802-3807.
23. Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, Anderson C, et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 2006; 24: 3157-3163.
24. Prometheus Laboratories Inc. Proleukin [package insert]. San Diego, CA: Prometheus Laboratories Inc.; Available at : http://www.proleukin.com/assets/ proleukin.pdf [Accessed 18 July 2011]; 2010.
25. Guleria AS, Yang JC, Tolapian SL, Weber JS, Parkinson DR, MacFarlane MP, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994; 12:2714-2722.
26. White RL, Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E, et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74:3212-3222.
27. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenberg SA. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 1993; 11:136-147.
28. Macfarlane MP, Yang JC, Guleria AS, White RL Jr, Seipp CA, Einhorn JH, et al. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer 1995; 75:1030-1037.
29. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995; 18:272-278.
30. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1998; 318:1557-1563.
31. Kim-Schulze S, Taback B, Kaufman HL. Cytokine therapy for cancer. Surg Oncol Clin N Am 2007; 16:793-818.
32. Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997; 3 (Suppl 1):S92-S97.
33. Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996; 2:91-98.
34. Chavez ARV, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, et al. Pharmacologic administration of interleukin-2: inducing a systemic autophagic syndrome? Ann N Y Acad Sci 2009; 1182:14-27.
35. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. Cancer 2008; 113:293-301.
36. Michel M, Vincent F, Sigal R, Damaj G, Bensousan TA, Leclercq B, et al. Cerebral vasculitis after interleukin-2 therapy for renal cell carcinoma. J Immunother 1995; 18:124-126.
37. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokineactivated killer cells. Ann Intern Med 1987; 107:293-300.
38. Saris SC, Patronas NJ, Rosenberg SA, Alexander JT, Frank J, Schwartzentruber DJ, et al. The effect of intravenous interleukin-2 on brain water content. J Neurosurg 1989; 71:169-174.
39. Bernard JT, Ameriso S, Kempf RA, Rosen P, Mitchell MS, Fisher M. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990; 40:154-155.
40. Vecht CJ, Keohane C, Menon RS, Henzen-Logmans SC, Punt CJA, Stoter G. Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med 1990; 323:1146-1147.
41. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon-alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759.
42. Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J Immunother Emphasis Tumor Immunol 1994; 16:60-65.
43. O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999; 17:2752-2761.
44. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin-2, and IFN-α2b in patients with metastatic melanoma. Clin Cancer Res 2002; 8:3075-3081.
45. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KF, Saleemi KR, Freeman LM, et al. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J Clin Oncol 1990; 8:1839-1846.
46. Geertsen PF, von der Maase H, Olsen NV, Fogh-Andersen N, Nielsen SL, Leyssac PP. Renal haemodynamics, sodium and water reabsorption during continuous intravenous infusion of recombinant interleukin-2. Clin Sci (Lond) 1998; 95:73-81.
47. Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, et al. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol 1994; 15:22-28.
48. Memoli B, De Nicola L, Libetta C, Scialo A, Pacchiano G, Romano P, et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by lowdose dopamine infusion. Am J Kidney Dis 1995; 26:27-33.
49. Cormier JN, Hurst R, Vasselli J, Lee D, Kim CJ, McKee M, et al. A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. J Immunother 1997; 20: 292-300.
50. Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, DiBisceglie AM, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 1989; 7:1852-1862.
51. Richard V, Bernier M, Themelin L, Bron D, Sculier J-R. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]). Ann Oncol 1991; 2:67-68.
52. Birchfield GR, Rodgers GM, Girodias KW, Ward JG, Samlowski WE. Hypoprothrombinemia associated with interleukin-2 therapy: correction with vitamin K. J Immunother 1992; 11:71-75.
53. Kwong LK, Ridinger DN, Bandhauer M, Ward JH, Samlowski WE, Iverius P-H, et al. Acute dyslipoproteinemia induced by interleukin-2: lecithin:cholesteryl acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies. J Clin Endocrinol Metab 1997; 82:1572-1581.
54. Ballmer-Weber BK, Kung E, Dummer R, Burg G, Ballmer PE. Interleukin-2 induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer 1995; 71:78-82.
55. Schwartzentruber DJ. Guidelines for the safe administration of high dose interleukin 2. J Immunother 2001; 24:287-293.
56. Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 2001; 7:2611-2619.
57. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990; 322:959-965.
58. Bock SN, Lee RE, Fisher B, Rubin JT, Schwartzentruber DJ, Wei JP, et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 1990; 8:161-169.
59. Hartmann LC, Urba WJ, Steis R, Smith JW, VanderMolen LA, Creekmore SP, et al. Use of prophylactic antibiotics for prevention of intravascular catheterrelated infections in interleukin-2 treated patients. J Nat Cancer Inst 1989; 81:1190-1193.
60. Esteva-Lorenzo F, Janik J, Fenton R, Emslie-Smith A, Engel A, Longo D. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer (Phila) 1995; 76:1219-1223.
61. Anderlini P, Buzaid A, Legha S. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-a, and chemotherapy for metastatic melanoma. Cancer (Phila) 1995; 76:678-679.
62. Greenfield SM, Harvey RS, Thompson RPH. Rhabdomyolysis after treatment with interferon alpha. Br Med J 1994; 309:512.
63. Reinhold U, Hartl C, Hering R, Hoeft A, Kreysel HW. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferonalpha in malignant melanoma. Lancet 1997; 349:540-541.
64. Lee SH, Baig M, Ruscino V, Dutcher JP. Novel management of pruritus in patients treated with IL-2 for metastatic renal cell carcinoma and malignant melanoma. J Immunother 2010; 33:1010-1013.
65. Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009; 361:1415-1416.
66. Greaves MW. Pathogenesis and treatment of pruritis. Curr Allergy Asthma Rep 2010; 10:236-242.
67. Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5:e10968.
68. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. J Am Med Assoc 1987; 258:1624-1629.
69. Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB. Nosocomial sepsis associated with interleukin-2. Ann Intern Med 1990; 112:102-107.
70. Murphy PM, Lane HC, Gallin JI, Fauci AS. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma. Ann Intern Med 1988; 108:36-41.
71. Pichert G, Jost LM, Zobeli L, Odermatt B, Pedia G, Stahel RA. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer 1990; 62:100-104.
72. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477-3482.
73. Denicoff KD, Durkin TM, Lotze MT, Quinlan PE, Davis CL, Listwak SJ, et al. The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 1989; 69:402-410.
74. VanderMolen LA, Smith JW, Longo DL, Steis RG, Kremers P, Sznol M. Adrenal insufficiency and interleukin-2 therapy. Ann Intern Med 1989; 111:185.
75. Wilson DE, Birchfield GR, Hejazi JS, Ward JH, Samlowski WE. Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins. J Clin Oncol 1989; 7: 1573-1577.
76. Kwong LK, Ridinger DN, Bandhauer M, Ward JH, Samlowski WE, Iverius PH, et al. Acute dyslipoproteinemia induced by interleukin-2: lecithin:cholesteryl acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies. J Clin Endocrinol Metab 1997; 82:1572-1581.
77. Webb DE, Austin HA, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988; 30:141-145.
78. Green MR, Woolery JE, Elquza E. Syndrome of inappropriate antidiuretic hormone secretion caused by high-dose bolus interleukin-2 for metastatic melanoma. Am J Ther 2011; 18:e159-e161.
79. Paciucci PA, Mandeli J, Oleskowicz L, Ameglio F, Holland JF. Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion. Am J Med 1990; 89:308-312.
80. Oleksowicz L, Zuckerman D, Mrowiec Z, Puszkin E, Dutcher JP. Effects of interleukin-2 administration on platelet function in cancer patients. Am J Hematol 1994; 45:224-231.
81. Gibbs P, Iannucci A, Becker M, Allen J, O'Driscoll M, McDowell K, et al. A phase II study of biochemotherapy for the treatment of metastatic melanoma. Melanoma Res 2000; 10:171-179.
82. Sculier JP, Bron D, Verboven N, Klatersky J. Multiple organ failure during IL-2 administration and LAK cell infusion. Intensive Care Med 1988; 14:666-667.
83. Fleischmann JD, Shingleton WB, Gallagher C, Ratnoff OD, Chahine A. Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. J Lab Clin Med 1991; 117:76-82.
84. Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, et al. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer 1991; 68:1538-1544.
85. Richard V, Bernier M, Themelin L, Bron D, Sculier JP. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]). Ann Oncol 1991; 2:67-68.
86. Oleksowicz L, Strack M, Dutcher JP, Sussman I, Caliendo G, Sparano J, et al. A distinct coagulopathy associated with interleukin-2 therapy. Br J Haematol 1994; 88:892-894.